Retinal Imaging Links Red-Light Myopia Therapy to Foveal Cone Loss
-
Click here to listen to this article - Share via
- Children receiving repeated low-level red-light therapy for myopia showed measurable loss of light-sensing cone cells near the central retina.
- Cellular-level changes were most pronounced in the temporal region of the fovea after one year or more of treatment.
- Standard clinical eye scans failed to catch early cone cell loss, which required advanced adaptive optics imaging to detect.
- A subset of eyes exposed to red-light devices showed structural signal abnormalities near the central retina.
- Structural changes in one patient resolved three months after stopping the light treatments, pointing to a need for clinical oversight.
Table of Contents
- High-Resolution Scans Reveal Microstructural Retinal Changes
- Foveal Cone Loss and Paracentral Signal Abnormalities
- The Research Gap in Pediatric Myopia Surveillance
- Clinical Implications for Pediatric Eye Care
- Closing Thoughts
High-Resolution Scans Reveal Microstructural Retinal Changes
Repeated low-level red-light therapy for myopia in children is linked to measurable foveal cone loss in the central retina, according to new high-resolution retinal imaging [1].
esearchers evaluated pediatric patients using adaptive optics scanning laser ophthalmoscopy (AOSLO), a high-resolution retinal imaging technique that visualizes individual photoreceptor cells in living eyes.
Quick Take & Core Data:
- Cone Cell Reduction: Children in the red-light group experienced a mean cone density loss of 2.1x10^3 cells/mm2 at 0.3 millimeters temporal to the foveal center compared with control subjects.
- Elevated Risk of Retinal Anomalies: Exposed eyes exhibited more than seven times higher odds of abnormal low-frequency, high-brightness signals near the fovea compared to non-exposed eyes.
- Cohort Size: The multicenter study analyzed 97 eyes from 52 children using red-light therapy and 74 eyes from 47 untreated control patients.
- Low-level red-light devices emit 650-nanometer red light through ocular desktop units [1, 4].
Children look into the device twice daily for three minutes per session to shorten axial elongation, the physical lengthening of the eyeball that drives childhood nearsightedness [1, 4].
Clinical trials show this treatment slows myopia progression, but the underlying safety margin is narrow. A 2024 optical safety analysis tested two commercial red-light myopia devices against American National Standards Institute laser exposure limits and found that about three minutes of continuous viewing approached or exceeded both the photochemical and thermal maximum permissible exposure thresholds for at least one device [2].
That margin comes from how much light energy reaches the retina relative to the exposure time regulators consider safe, not from any device malfunction.
A 2023 case report described a 12-year-old girl who developed bilateral vision loss after five months of red-light therapy, with retinal imaging showing disruption to the photoreceptor layer and reduced electrical responses in the macula [3].
Her vision partially recovered after she stopped treatment. The report also noted a competing explanation: she may have had an undiagnosed inherited retinal condition that light exposure unmasked rather than caused outright, leaving the exact mechanism of her injury unresolved.
Foveal Cone Loss and Paracentral Signal Abnormalities
The study demonstrated that photoreceptor loss occurred primarily within 0.5 millimeters of the central fovea [1]. The temporal retinal meridian showed the largest difference in cone cell density. At 0.3 millimeters temporal eccentricity, children receiving red-light therapy had a mean cone density drop of 2.1x10^3 cells/mm2 compared with non-users [1].
Cone Density Comparison at 0.3 mm Temporal Eccentricity
- Red-Light Therapy Group: Lower by 2,100 cells/mm² (mean)
- Statistical Confidence: 95% CI (-3,680 to -590 cells/mm²)
- P-value: P = 0.003
High-resolution imaging identified abnormal low-frequency, high-brightness signals in 11 eyes from the treatment group. The odds ratio for developing these structural signals was 7.23 among red-light users compared to untreated control subjects [1].
One participant developed cystoid abnormalities in the retinal ganglion cell layer, a light-processing inner layer of the retina, which cleared three months after stopping light exposure [1].
Recognizing early signs of structural retinal damage matters across pediatric and adult eye conditions alike, not only in red-light myopia therapy.
The Research Gap in Pediatric Myopia Surveillance
Previous clinical trials evaluated red-light safety using standard fundus photography and optical coherence tomography, a cross-sectional tissue imaging scan [1, 4]. These standard tools lack the microscopic resolution needed to view individual photoreceptors, so early cellular changes remained undetected in earlier safety evaluations.
AOSLO fills this gap by providing cellular-scale imaging of individual cone cells in vivo. This diagnostic tool exposes subclinical photoreceptor loss before larger structural tissue damage becomes visible.
Diagnostic Resolution Comparison
| Tool | Capability |
|---|---|
The primary limitation of this research is its retrospective cohort design: baseline pre-treatment adaptive optics scans were not available for the participants, so baseline cone densities could not be directly compared before light exposure began [1].
Establishing clear safety and efficacy endpoints in pediatric trials before treatment begins remains a broader challenge across pediatric interventions, not just red-light myopia therapy.
Clinical Implications for Pediatric Eye Care
These findings give clinicians concrete data to weigh when guiding families through myopia progression management choices. While red-light devices reduce axial length growth, cellular changes near the central visual field call for cautious monitoring [1, 4].
The study measured structural cone density on imaging, not functional vision outcomes such as visual acuity or color vision, so whether this cellular-level loss affects eyesight has not yet been established.
Ophthalmologists recommend establishing clear baseline retinal profiles before starting red-light treatments. Children undergoing daily light therapy may benefit from periodic high-resolution retinal imaging surveillance to spot early photoreceptor changes.
Parents should discuss potential safety risks with an eye care specialist before starting home-based red-light treatments.
Uneven pediatric care access across regions can also determine how quickly a family reaches that specialist input.
Closing Thoughts
Objective analysis of any myopic progression intervention requires balancing structural preservation with optical benefits. New technologies offer additional ways to manage ocular elongation, but rigorous cellular monitoring remains paramount for patient safety.
High-resolution adaptive optics imaging reveals that repeated low-level red light therapy for childhood myopia is tied to localized foveal cone cell loss and subtle retinal anomalies. Balancing the proven benefits of slowing myopia progression against potential cellular photothermal risks requires ongoing surveillance and cautious clinical management.
References
[1]. Liao, X., Yu, J., Fan, Y., Zhang, Y., Li, Y., Li, X., Song, H., & Wang, K. (2025). Cone density changes after repeated low-level red light treatment in children with myopia. JAMA Ophthalmology, 143(6), 480–488. https://doi.org/10.1001/jamaophthalmol.2025.0835
[2]. Ostrin, L. A., & Schill, A. W. (2024). Red light instruments for myopia exceed safety limits. Ophthalmic and Physiological Optics, 44(2), 241–248. https://doi.org/10.1111/opo.13272
[3]. Liu, H., Yang, Y., Guo, J., Peng, J., & Zhao, P. (2023). Retinal damage after repeated low-level red-light laser exposure. JAMA Ophthalmology, 141(7), 693–695. https://doi.org/10.1001/jamaophthalmol.2023.1548
[4]. Jiang, Y., Zhu, Z., Tan, X., Kong, X., Zhong, H., Zhang, J., Xiong, R., Yuan, Y., Zeng, J., Morgan, I. G., & He, M. (2022). Effect of repeated low-level red-light therapy for myopia control in children: A multicenter randomized controlled trial. Ophthalmology, 129(5), 509–519. https://doi.org/10.1016/j.ophtha.2021.11.023
